Suprelorin, animal contraceptive 2×4.7 mg (deslorelin)
Composition and form of release
The non-steroidal contraceptive contains 4.7 mg deslorelin (acetate) as the active ingredient. Excipients: hydrogenated palm oil, lecithin, anhydrous sodium acetate.
The drug is a white or pale yellow cylindrical implant that is inserted under the skin by a veterinarian.
The implant is supplied with pre-charged implanter needles. Each needle is packed in a sealed sterile package. The cardboard box contains two sterile individual needles for implantation, as well as a device (drive) that is not sterilized. The actuator is attached to the needle with a threaded connection.
Pharmacological properties
Pharmacotherapeutic group: gonadotropin-releasing hormone (LH).
Suprelorin is a non-steroidal contraceptive.
The GnRH antagonist deslorelin acts by suppressing the function of the pituitary gland, germ cells, when used in low, continuous doses. This leads to suppression of the ability of experimental animals to synthesize and / or release follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which are responsible for maintaining fertility. Continuous release of low doses of deslorelin from the implant reduces the functionality of the male genital organs, libido and spermatogenesis. The decrease in plasma testosterone levels occurs 4-6 weeks after implantation. A short-term (passing) increase in testosterone in blood plasma can be immediately after implantation. Plasma testosterone concentration measurements have demonstrated a persistent pharmacological effect of constant presence of deslorelin for at least six months after drug administration.
Plasma deslorelin levels have been shown to occur between 7 and 35 days after implant placement. The drug can be measured in plasma up to about 2.5 months after implantation. Deslorelin is rapidly metabolized.
Indications
It is used to induce temporary infertility in healthy, sexually mature male dogs, cats and ferrets. Temporary sterilization is indispensable in the case when the mating of the animal is undesirable at the present time (for example, the owners of the kennels) or simply the owners of the animals do not want to perform surgical neutering of their pet.
The introduction of the implant allows you to suppress sexual function for at least 6 months.
In addition, Suprelorin is used to treat adrenal diseases (a common problem in ferrets).
Doses and method of administration
The route of administration is subcutaneous. Similar to the procedure for chipping animals. The recommended dose is one implant per dog, regardless of size. When administering the drug, aseptic and antiseptic measures must be observed. If the hair is long, a small section should be trimmed if required. Remove the protective cap at the base of the needle. Attach the needle to the implanter with a threaded connection.
Suprelorin can be implanted under the skin on the back between the neck and lumbar region. Avoid inserting the implant into the fat, as the release of the active substance can be impaired in the area of low vascularity. Lift up the area of skin between your shoulder blades. Insert the entire length of the needle subcutaneously. Fully push the plunger and slowly withdraw the needle. Press the skin at the insertion site while the needle is being removed and maintain the pressure for 30 seconds. Check the syringe and needle to make sure the implant does not remain in the needle and the spacer is visible. It may be possible to palpate the implant at the insertion site.
Repeat the procedure every six months to maintain effectiveness. Biocompatible implants do not need to be removed. However, if it is necessary to stop treatment, the implant can be removed surgically. It can be detected using ultrasound.
Special warnings: Infertility is achieved 6 weeks after administration of the drug and continues for at least 6 months after injection. Treated males should still be kept away from bitches for the first six weeks after implant placement. Any mating, if it occurs more than six months after drug administration, can lead to pregnancy. If the product is given every 6 months, bitches and males can be kept together. The ability of dogs to reproduce after they return to normal plasma testosterone levels following drug administration has not been investigated. In terms of testosterone (a surrogate marker of fertility), in clinical trials, more than 80% of dogs returned to normal plasma testosterone levels after one or more implants (= 0, 4 ng / ml) for 12 months. 98% of dogs returned to normal plasma testosterone levels within 18 months of implantation. However, there is limited evidence of a complete reversibility of the clinical effect (decrease in testicular size, decrease in ejaculation volume, decrease in sperm count and decrease in libido), including fertility after six months or repeated implantations, are limited. In clinical trials, most smaller dogs (less than 10 kg) maintained low testosterone levels for more than 12 months after implantation. For very large dogs (> 40 kg), data are limited, but the duration of testosterone suppression was comparable to that of medium to large dogs. However, there is limited evidence of a complete reversibility of the clinical effect (decrease in testicular size, decrease in ejaculation volume, decrease in sperm count and decrease in libido), including fertility after six months or repeated implantations, are limited. In clinical trials, most smaller dogs (less than 10 kg) maintained low testosterone levels for more than 12 months after implantation. For very large dogs (> 40 kg), data are limited, but the duration of testosterone suppression was comparable to that of medium to large dogs. However, there is limited evidence of a complete reversibility of the clinical effect (decrease in testicular size, decrease in ejaculation volume, decrease in sperm count and decrease in libido), including fertility after six months or repeated implantations, are limited. In clinical trials, most smaller dogs (less than 10 kg) maintained low testosterone levels for more than 12 months after implantation. For very large dogs (> 40 kg), data are limited, but the duration of testosterone suppression was comparable to that of medium to large dogs. In clinical trials, most smaller dogs (less than 10 kg) maintained low testosterone levels for more than 12 months after implantation. For very large dogs (> 40 kg), data are limited, but the duration of testosterone suppression was comparable to that of medium to large dogs. In clinical trials, most smaller dogs (less than 10 kg) maintained low testosterone levels for more than 12 months after implantation. For very large dogs (> 40 kg), data are limited, but the duration of testosterone suppression was comparable to that of medium to large dogs.
Use of Suprelorin in dogs less than 10 kg or more than 40 kg body weight should be evaluated by a veterinarian.
Overdose:
No adverse reactions were observed after simultaneous subcutaneous administration of up to 10 implants.
Side effects
Moderate swelling at the site of implantation can be observed for up to 14 days.
In some males, a local reaction was found histologically with chronic inflammation of the connective tissue and the formation of a collagen capsule 3 months after administration. A significant decrease in the size of the testes will be seen throughout the treatment period. In very rare cases, the testicle may rise above the outer inguinal ring.
Contraindications
It is unacceptable to use during pregnancy, lactation.
special instructions
Interaction with other medicinal products: None known.
Special precautions:
Use of the product in adolescent dogs has not been investigated. Therefore, it is recommended that dogs must be fully matured prior to using Suprelorin. Data show that product use can reduce a dog’s libido, but other behavioral changes (such as those associated with aggression) have not been investigated.
Special precautions for the destruction of veterinary medicinal products:
Any unused veterinary medicinal product and waste resulting from such veterinary medicinal products should be disposed of in accordance with local requirements.
The drive can be reused.
Personal safety measures
Special precautions must be taken by those handling this veterinary drug.
Pregnant women should not work with the drug.
No specific studies have been conducted to evaluate the effect of deslorelin when taken during pregnancy.
Although skin contact with the product is unlikely to occur, if this occurs, wash the affected area immediately as GnRH analogs can be absorbed through the skin.
When handling Suprelorin, use caution to avoid accidental self-injection. The animal must be properly restrained and the drug needle protected until implantation. In case of accidental self-injection, consult a doctor immediately.
Storage conditions
Store the medicinal product in the manufacturer’s sealed packaging, protected from light, out of reach of children and animals, separately from food and feed at a temperature of 2 ° C to 8 ° C. Do not freeze.
Do not use the product if the packaging is broken